- Home
- ASAN vs CNTA Comparison
ASAN vs CNTA Comparison
Compare ASAN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | CNTA |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASAN | CNTA |
|---|---|---|
| Price | $7.65 | $25.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $16.17 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 5.1M | 1.5M |
| Earning Date | 03-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $723,876,000.00 | N/A |
| Revenue This Year | $11.39 | N/A |
| Revenue Next Year | $8.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.94 | N/A |
| 52 Week Low | $7.15 | $9.60 |
| 52 Week High | $22.27 | $30.58 |
Technical Indicators
Market Signals| Indicator | ASAN | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 24.01 | 56.34 |
| Support Level | $7.15 | $22.50 |
| Resistance Level | $7.88 | $25.80 |
| Average True Range (ATR) | 0.57 | 1.29 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 14.37 | 63.34 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.